Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 29;9(13):eade8778. doi: 10.1126/sciadv.ade8778

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

This is an open-access article distributed under the terms of the Creative Commons Attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1. — (A) Relative frequency of amino acid changes at P168, excluding proline (open circle), in SARS2 genomes (1 July 2022, GISAID database). (B) Cocrystal structures of SARS2 M^pro in complex with boceprevir (PDB: 6WNP), nirmatrelvir (PDB: 7SI9), and ensitrelvir (PDB: 7VU6). (C) Dose-response curves of WT, P168S, and ∆P168 M^pro variants using the live-cell Src-M^pro-Tat-fLuc assay with fourfold serial dilution of inhibitor beginning at 10 μM for nirmatrelvir and ensitrelvir or 100 μM for boceprevir (data are means ± SD of biologically independent triplicate experiments). (D) Relative luminescence of cells expressing Src-M^pro-Tat-fLuc variants in the absence of inhibitor. (E) Dose-response curves of nirmatrelvir and ensitrelvir against WT and ∆P168 M^pro in an orthologous VSV-based M^pro cis-cleavage assay (data are means ± SD of biologically independent triplicate experiments).